Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer
Categories (click each to see list of all clinical trials associated with that category): Radiation Oncology (RADONC), Thoracic (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Zhen, Weining
Contact Information:
Trevor Beard
tbeard@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06686771?term=NCT06686771&rank=1#participation-criteria
Summary
PRIMARY OBJECTIVES:
I. Progression-free survival [Time Frame: 5.5 years]
II. Overall survival [Time Frame: 5.5 years]
SECONDARY OBJECTIVES:
I. Number and severity of adverse events [Time Frame: 5.5 years]
II. Patient-reported adverse events utilizing PRO-CTCAE questionnaire [Time Frame: 5.5 years]
III. Patient-reported quality of life utilizing EORTC-QLQ-C30 questionnaire [Time Frame: 5.5 years]
IV. Patient-reported quality of life utilizing QLQ-LC-13 questionnaire [Time Frame: 5.5 years]